Nguyen Stephanie
Haematology and Cellular Therapies Department, AP-HP Sorbonne University, Pitie Salpetriere Hospital, 47-83 bvd de l'hopital, 75651, Paris Cedex 13, France.
Patient Author, Paris, France.
Oncol Ther. 2025 Aug 25. doi: 10.1007/s40487-025-00364-0.
This collaborative article is co-authored by a haematologist and her patient who was immunocompromised following a bone marrow transplant for acute myeloid leukaemia (AML), which was probably chemotherapy-induced following treatment for a BReast CAncer gene 1 (BRCA1)-mutated breast cancer. The patient shares her story of resilience up to her AML diagnosis and treatment, through the bone marrow transplant, and then on to the challenges faced as an immunocompromised patient during the coronavirus disease 2019 (COVID-19) pandemic. The haematologist offers detailed insights into AML and treatment options, including chemotherapy and allogeneic haematopoietic stem cell transplantation. She comments on the challenging journey of her patient, and the complexities of managing immunocompromised patients during the pandemic, who failed to respond sufficiently to vaccination. In addition, she outlines the prophylactic strategy implemented in her centre, and the introduction of alternative immunisation with monoclonal antibodies for this high-risk immunocompromised patient population. This case provides a unique combination of personal patient experience during the COVID-19 pandemic and medical insights.
这篇合作文章由一位血液学家及其患者共同撰写。该患者在接受急性髓系白血病（AML）的骨髓移植后免疫功能受损，而AML可能是在治疗BRCA1基因（乳腺癌1号基因）突变的乳腺癌后由化疗引起的。患者分享了她从AML诊断和治疗，到骨髓移植，再到在2019冠状病毒病（COVID-19）大流行期间作为免疫功能受损患者所面临挑战的坚韧历程。血液学家详细介绍了AML及治疗方案，包括化疗和异基因造血干细胞移植。她评论了患者充满挑战的历程，以及在大流行期间管理免疫功能受损患者的复杂性，这些患者对疫苗接种反应不足。此外，她概述了其所在中心实施的预防策略，以及为这一高风险免疫功能受损患者群体引入单克隆抗体替代免疫接种的情况。本病例提供了COVID-19大流行期间患者个人经历与医学见解的独特结合。
